{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:49:29Z","timestamp":1790808569669,"version":"4.1.0"},"reference-count":266,"publisher":"Aging and Disease","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2025]]},"DOI":"10.14336\/ad.2024.1688","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T17:02:22Z","timestamp":1741885342000},"page":"0","source":"Crossref","is-referenced-by-count":3,"title":["Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy"],"prefix":"10.14336","author":[{"given":"Weiyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqing","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunming","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2024.1688-1","doi-asserted-by":"crossref","unstructured":"Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. (2022). World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. Int J Stroke, 17:18-29.","DOI":"10.1177\/17474930211065917"},{"key":"key-10.14336\/AD.2024.1688-2","doi-asserted-by":"crossref","unstructured":"The Lancet N (2023). Brain health, disability, and the need for broader thinking. Lancet Neurol, 22:769.","DOI":"10.1016\/S1474-4422(23)00236-3"},{"key":"key-10.14336\/AD.2024.1688-3","doi-asserted-by":"crossref","unstructured":"Furie B, Furie BC (2008). Mechanisms of thrombus formation. N Engl J Med, 359:938-949.","DOI":"10.1056\/NEJMra0801082"},{"key":"key-10.14336\/AD.2024.1688-4","doi-asserted-by":"crossref","unstructured":"Alkarithi G, Duval C, Shi Y, Macrae FL, Ariens RAS (2021). Thrombus Structural Composition in Cardiovascular Disease. Arterioscler Thromb Vasc Biol, 41:2370-2383.","DOI":"10.1161\/ATVBAHA.120.315754"},{"key":"key-10.14336\/AD.2024.1688-5","doi-asserted-by":"crossref","unstructured":"Levine MN, Lee AY, Kakkar AK (2003). From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost, 1:1456-1463.","DOI":"10.1046\/j.1538-7836.2003.00275.x"},{"key":"key-10.14336\/AD.2024.1688-6","doi-asserted-by":"crossref","unstructured":"Lowe GD (2007). Update on the cardiovascular risks of hormone replacement therapy. Womens Health (Lond), 3:87-97.","DOI":"10.2217\/17455057.3.1.87"},{"key":"key-10.14336\/AD.2024.1688-7","doi-asserted-by":"crossref","unstructured":"Samad F, Ruf W (2013). Inflammation, obesity, and thrombosis. Blood, 122:3415-3422.","DOI":"10.1182\/blood-2013-05-427708"},{"key":"key-10.14336\/AD.2024.1688-8","doi-asserted-by":"crossref","unstructured":"Ambrose JA, Barua RS (2004). The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol, 43:1731-1737.","DOI":"10.1016\/j.jacc.2003.12.047"},{"key":"key-10.14336\/AD.2024.1688-9","doi-asserted-by":"crossref","unstructured":"Uzuner N, Uzuner GT (2023). Risk factors for multiple recurrent ischemic strokes. Brain Circulation, 9.","DOI":"10.4103\/bc.bc_73_22"},{"key":"key-10.14336\/AD.2024.1688-10","doi-asserted-by":"crossref","unstructured":"Kyrle PA, Rosendaal FR, Eichinger S (2010). Risk assessment for recurrent venous thrombosis. Lancet, 376:2032-2039.","DOI":"10.1016\/S0140-6736(10)60962-2"},{"key":"key-10.14336\/AD.2024.1688-11","doi-asserted-by":"crossref","unstructured":"Bryckaert M, Rosa JP, Denis CV, Lenting PJ (2015). Of von Willebrand factor and platelets. Cell Mol Life Sci, 72:307-326.","DOI":"10.1007\/s00018-014-1743-8"},{"key":"key-10.14336\/AD.2024.1688-12","doi-asserted-by":"crossref","unstructured":"Nieswandt B, Watson SP (2003). Platelet-collagen interaction: is GPVI the central receptor? Blood, 102:449-461.","DOI":"10.1182\/blood-2002-12-3882"},{"key":"key-10.14336\/AD.2024.1688-13","doi-asserted-by":"crossref","unstructured":"Semple JW, Italiano JE, Jr., Freedman J (2011). Platelets and the immune continuum. Nat Rev Immunol, 11:264-274.","DOI":"10.1038\/nri2956"},{"key":"key-10.14336\/AD.2024.1688-14","doi-asserted-by":"crossref","unstructured":"Stefanini L, Bergmeier W (2019). RAP GTPases and platelet integrin signaling. Platelets, 30:41-47.","DOI":"10.1080\/09537104.2018.1476681"},{"key":"key-10.14336\/AD.2024.1688-15","doi-asserted-by":"crossref","unstructured":"Shattil SJ, Newman PJ (2004). Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood, 104:1606-1615.","DOI":"10.1182\/blood-2004-04-1257"},{"key":"key-10.14336\/AD.2024.1688-16","doi-asserted-by":"crossref","unstructured":"Stark K, Philippi V, Stockhausen S, Busse J, Antonelli A, Miller M, et al. (2016). Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood, 128:2435-2449.","DOI":"10.1182\/blood-2016-04-710632"},{"key":"key-10.14336\/AD.2024.1688-17","doi-asserted-by":"crossref","unstructured":"Carestia A, Kaufman T, Schattner M (2016). Platelets: New Bricks in the Building of Neutrophil Extracellular Traps. Front Immunol, 7:271.","DOI":"10.3389\/fimmu.2016.00271"},{"key":"key-10.14336\/AD.2024.1688-18","doi-asserted-by":"crossref","unstructured":"Chandrashekar A, Singh G, Jonah G, Sikalas N, Labropoulos N (2018). Mechanical and Biochemical Role of Fibrin Within a Venous Thrombus. Eur J Vasc Endovasc Surg, 55:417-424.","DOI":"10.1016\/j.ejvs.2017.12.002"},{"key":"key-10.14336\/AD.2024.1688-19","doi-asserted-by":"crossref","unstructured":"Zhmurov A, Protopopova AD, Litvinov RI, Zhukov P, Weisel JW, Barsegov V (2018). Atomic Structural Models of Fibrin Oligomers. Structure, 26:857-868.e854.","DOI":"10.1016\/j.str.2018.04.005"},{"key":"key-10.14336\/AD.2024.1688-20","doi-asserted-by":"crossref","unstructured":"Stark K, Massberg S (2021). Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol, 18:666-682.","DOI":"10.1038\/s41569-021-00552-1"},{"key":"key-10.14336\/AD.2024.1688-21","doi-asserted-by":"crossref","unstructured":"Wu C, Lu W, Zhang Y, Zhang G, Shi X, Hisada Y, et al. (2019). Inflammasome Activation Triggers Blood Clotting and Host Death through Pyroptosis. Immunity, 50:1401-1411.e1404.","DOI":"10.1016\/j.immuni.2019.04.003"},{"key":"key-10.14336\/AD.2024.1688-22","doi-asserted-by":"crossref","unstructured":"Duerschmied D, Suidan GL, Demers M, Herr N, Carbo C, Brill A, et al. (2013). Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood, 121:1008-1015.","DOI":"10.1182\/blood-2012-06-437392"},{"key":"key-10.14336\/AD.2024.1688-23","doi-asserted-by":"crossref","unstructured":"Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, et al. (1992). Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature, 359:848-851.","DOI":"10.1038\/359848a0"},{"key":"key-10.14336\/AD.2024.1688-24","doi-asserted-by":"crossref","unstructured":"Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Jr., et al. (2010). Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A, 107:15880-15885.","DOI":"10.1073\/pnas.1005743107"},{"key":"key-10.14336\/AD.2024.1688-25","doi-asserted-by":"crossref","unstructured":"von Br\u00fchl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. (2012). Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med, 209:819-835.","DOI":"10.1084\/jem.20112322"},{"key":"key-10.14336\/AD.2024.1688-26","doi-asserted-by":"crossref","unstructured":"Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, et al. (2010). Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med, 16:887-896.","DOI":"10.1038\/nm.2184"},{"key":"key-10.14336\/AD.2024.1688-27","doi-asserted-by":"crossref","unstructured":"Mackman N (2012). New insights into the mechanisms of venous thrombosis. J Clin Invest, 122:2331-2336.","DOI":"10.1172\/JCI60229"},{"key":"key-10.14336\/AD.2024.1688-28","doi-asserted-by":"crossref","unstructured":"Chiu JJ, Chien S (2011). Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev, 91:327-387.","DOI":"10.1152\/physrev.00047.2009"},{"key":"key-10.14336\/AD.2024.1688-29","doi-asserted-by":"crossref","unstructured":"Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi T, Kumari B, et al. (2017). Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proc Natl Acad Sci U S A, 114:4763-4768.","DOI":"10.1073\/pnas.1620458114"},{"key":"key-10.14336\/AD.2024.1688-30","doi-asserted-by":"crossref","unstructured":"Subramaniam S, Jurk K, Hobohm L, J\u00e4ckel S, Saffarzadeh M, Schwierczek K, et al. (2017). Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood, 129:2291-2302.","DOI":"10.1182\/blood-2016-11-749879"},{"key":"key-10.14336\/AD.2024.1688-31","doi-asserted-by":"crossref","unstructured":"Lippi G, Franchini M, Targher G (2011). Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol, 8:502-512.","DOI":"10.1038\/nrcardio.2011.91"},{"key":"key-10.14336\/AD.2024.1688-32","doi-asserted-by":"crossref","unstructured":"Mackman N (2008). Triggers, targets and treatments for thrombosis. Nature, 451:914-918.","DOI":"10.1038\/nature06797"},{"key":"key-10.14336\/AD.2024.1688-33","doi-asserted-by":"crossref","unstructured":"Watson T, Shantsila E, Lip GY (2009). Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet, 373:155-166.","DOI":"10.1016\/S0140-6736(09)60040-4"},{"key":"key-10.14336\/AD.2024.1688-34","doi-asserted-by":"crossref","unstructured":"Gu Z, Yin A, Lu L, Lu Y, Jiang B, Yin L (2024). Risk factors for intraprocedural hypoxemia in patients with acute cerebral ischemia treated with vascular intervention and its impact on prognosis: A retrospective cohort study. Brain Circulation, 10.","DOI":"10.4103\/bc.bc_50_23"},{"key":"key-10.14336\/AD.2024.1688-35","doi-asserted-by":"crossref","unstructured":"Thomson RM, Anderson DC (2013). Aspirin and clopidogrel for prevention of ischemic stroke. Curr Neurol Neurosci Rep, 13:327.","DOI":"10.1007\/s11910-012-0327-y"},{"key":"key-10.14336\/AD.2024.1688-36","doi-asserted-by":"crossref","unstructured":"Versteeg HH, Heemskerk JW, Levi M, Reitsma PH (2013). New fundamentals in hemostasis. Physiol Rev, 93:327-358.","DOI":"10.1152\/physrev.00016.2011"},{"key":"key-10.14336\/AD.2024.1688-37","doi-asserted-by":"crossref","unstructured":"Gurbel PA, Kuliopulos A, Tantry US (2015). G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol, 35:500-512.","DOI":"10.1161\/ATVBAHA.114.303412"},{"key":"key-10.14336\/AD.2024.1688-38","doi-asserted-by":"crossref","unstructured":"Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, et al. (2012). Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv, 5:347-356.","DOI":"10.1161\/CIRCINTERVENTIONS.111.965608"},{"key":"key-10.14336\/AD.2024.1688-39","doi-asserted-by":"crossref","unstructured":"Caroff E, Hubler F, Meyer E, Renneberg D, Gnerre C, Treiber A, et al. (2015). 4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. J Med Chem, 58:9133-9153.","DOI":"10.1021\/acs.jmedchem.5b00933"},{"key":"key-10.14336\/AD.2024.1688-40","doi-asserted-by":"crossref","unstructured":"Juif PE, Boehler M, Dobrow M, Ufer M, Dingemanse J (2019). Clinical Pharmacology of the Reversible and Potent P2Y(12) Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects. J Clin Pharmacol, 59:123-130.","DOI":"10.1002\/jcph.1296"},{"key":"key-10.14336\/AD.2024.1688-41","doi-asserted-by":"crossref","unstructured":"Storey RF, Gurbel PA, Ten Berg J, Bernaud C, Dangas GD, Frenoux JM, et al. (2020). Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J, 41:3132-3140.","DOI":"10.1093\/eurheartj\/ehz807"},{"key":"key-10.14336\/AD.2024.1688-42","doi-asserted-by":"crossref","unstructured":"Boldron C, Besse A, Bordes MF, Tissandi\u00e9 S, Yvon X, Gau B, et al. (2014). N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist. J Med Chem, 57:7293-7316.","DOI":"10.1021\/jm500588w"},{"key":"key-10.14336\/AD.2024.1688-43","doi-asserted-by":"crossref","unstructured":"Delesque-Touchard N, Pflieger AM, Bonnet-Lignon S, Millet L, Salel V, Boldron C, et al. (2014). SAR216471, an alternative to the use of currently available P2Y\u2081\u2082 receptor inhibitors? Thromb Res, 134:693-703.","DOI":"10.1016\/j.thromres.2014.06.034"},{"key":"key-10.14336\/AD.2024.1688-44","doi-asserted-by":"crossref","unstructured":"Kong D, Xue T, Guo B, Cheng J, Liu S, Wei J, et al. (2019). Optimization of P2Y(12) Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties. J Med Chem, 62:3088-3106.","DOI":"10.1021\/acs.jmedchem.8b01971"},{"key":"key-10.14336\/AD.2024.1688-45","doi-asserted-by":"crossref","unstructured":"Bird JE, Wang X, Smith PL, Barbera F, Huang C, Schumacher WA (2012). A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis. J Thromb Thrombolysis, 34:199-207.","DOI":"10.1007\/s11239-012-0745-3"},{"key":"key-10.14336\/AD.2024.1688-46","doi-asserted-by":"crossref","unstructured":"Costanzi S, Santhosh Kumar T, Balasubramanian R, Kendall Harden T, Jacobson KA (2012). Virtual screening leads to the discovery of novel non-nucleotide P2Y\u2081 receptor antagonists. Bioorg Med Chem, 20:5254-5261.","DOI":"10.1016\/j.bmc.2012.06.044"},{"key":"key-10.14336\/AD.2024.1688-47","doi-asserted-by":"crossref","unstructured":"Baqi Y, M\u00fcller CE (2012). Convergent synthesis of the potent P2Y receptor antagonist MG 50-3-1 based on a regioselective Ullmann coupling reaction. Molecules, 17:2599-2615.","DOI":"10.3390\/molecules17032599"},{"key":"key-10.14336\/AD.2024.1688-48","doi-asserted-by":"crossref","unstructured":"Yang W, Wang Y, Lai A, Qiao JX, Wang TC, Hua J, et al. (2014). Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents. J Med Chem, 57:6150-6164.","DOI":"10.1021\/jm5006226"},{"key":"key-10.14336\/AD.2024.1688-49","doi-asserted-by":"crossref","unstructured":"Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VV, et al. (2016). Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol, 36:501-509.","DOI":"10.1161\/ATVBAHA.115.306885"},{"key":"key-10.14336\/AD.2024.1688-50","doi-asserted-by":"crossref","unstructured":"Yanachkov IB, Chang H, Yanachkova MI, Dix EJ, Berny-Lang MA, Gremmel T, et al. (2016). New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem, 107:204-218.","DOI":"10.1016\/j.ejmech.2015.10.055"},{"key":"key-10.14336\/AD.2024.1688-51","doi-asserted-by":"crossref","unstructured":"Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, et al. (2018). GLS-409, an Antagonist of Both P2Y(1) and P2Y(12), Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep, 8:14529.","DOI":"10.1038\/s41598-018-32797-1"},{"key":"key-10.14336\/AD.2024.1688-52","doi-asserted-by":"crossref","unstructured":"O'Donoghue ML, Bhatt DL, Wiviott SD, Goodman SG, Fitzgerald DJ, Angiolillo DJ, et al. (2011). Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation, 123:1843-1853.","DOI":"10.1161\/CIRCULATIONAHA.110.000786"},{"key":"key-10.14336\/AD.2024.1688-53","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Flather MD, O'Donoghue ML, Goto S, Fitzgerald DJ, Cura F, et al. (2011). Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation, 123:1854-1863.","DOI":"10.1161\/CIRCULATIONAHA.110.001404"},{"key":"key-10.14336\/AD.2024.1688-54","doi-asserted-by":"crossref","unstructured":"Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE (2007). SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia\/reperfusion injury in rat hearts. Basic Res Cardiol, 102:350-358.","DOI":"10.1007\/s00395-007-0653-4"},{"key":"key-10.14336\/AD.2024.1688-55","doi-asserted-by":"crossref","unstructured":"Kato Y, Kita Y, Hirasawa-Taniyama Y, Nishio M, Mihara K, Ito K, et al. (2003). Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol, 473:163-169.","DOI":"10.1016\/S0014-2999(03)01973-3"},{"key":"key-10.14336\/AD.2024.1688-56","doi-asserted-by":"crossref","unstructured":"Covic L, Misra M, Badar J, Singh C, Kuliopulos A (2002). Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med, 8:1161-1165.","DOI":"10.1038\/nm760"},{"key":"key-10.14336\/AD.2024.1688-57","doi-asserted-by":"crossref","unstructured":"Kuliopulos A, Covic L (2003). Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis. Life Sci, 74:255-262.","DOI":"10.1016\/j.lfs.2003.09.012"},{"key":"key-10.14336\/AD.2024.1688-58","doi-asserted-by":"crossref","unstructured":"Kuliopulos A, Gurbel PA, Rade JJ, Kimmelstiel CD, Turner SE, Bliden KP, et al. (2020). PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol, 40:2990-3003.","DOI":"10.1161\/ATVBAHA.120.315168"},{"key":"key-10.14336\/AD.2024.1688-59","doi-asserted-by":"crossref","unstructured":"Wilson SJ, Ismat FA, Wang Z, Cerra M, Narayan H, Raftis J, et al. (2018). PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol, 38:448-456.","DOI":"10.1161\/ATVBAHA.117.310104"},{"key":"key-10.14336\/AD.2024.1688-60","doi-asserted-by":"crossref","unstructured":"Merali S, Wang Z, Frost C, Meadows-Shropshire S, Hawthorne D, Yang J, et al. (2023). First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants. Platelets, 34:2222846.","DOI":"10.1080\/09537104.2023.2222846"},{"key":"key-10.14336\/AD.2024.1688-61","doi-asserted-by":"crossref","unstructured":"Lin YC, Ko YC, Hung SC, Lin YT, Lee JH, Tsai JY, et al. (2019). Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog. Arterioscler Thromb Vasc Biol, 39:694-703.","DOI":"10.1161\/ATVBAHA.118.311758"},{"key":"key-10.14336\/AD.2024.1688-62","doi-asserted-by":"crossref","unstructured":"Massberg S, Gawaz M, Gr\u00fcner S, Schulte V, Konrad I, Zohlnh\u00f6fer D, et al. (2003). A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med, 197:41-49.","DOI":"10.1084\/jem.20020945"},{"key":"key-10.14336\/AD.2024.1688-63","doi-asserted-by":"crossref","unstructured":"Mazighi M, K\u00f6hrmann M, Lemmens R, Lyrer PA, Molina CA, Richard S, et al. (2024). Safety and efficacy of platelet glycoprotein VI inhibition in acute ischemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b\/2a trial. Lancet Neurol, 23:157-167.","DOI":"10.1016\/S1474-4422(23)00427-1"},{"key":"key-10.14336\/AD.2024.1688-64","doi-asserted-by":"crossref","unstructured":"Goebel S, Li Z, Vogelmann J, Holthoff HP, Degen H, Hermann DM, et al. (2013). The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. PLoS One, 8:e66960.","DOI":"10.1371\/journal.pone.0066960"},{"key":"key-10.14336\/AD.2024.1688-65","doi-asserted-by":"crossref","unstructured":"Ungerer M, Rosport K, B\u00fcltmann A, Piechatzek R, Uhland K, Schlieper P, et al. (2011). Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation, 123:1891-1899.","DOI":"10.1161\/CIRCULATIONAHA.110.980623"},{"key":"key-10.14336\/AD.2024.1688-66","doi-asserted-by":"crossref","unstructured":"Uphaus T, Richards T, Weimar C, Neugebauer H, Poli S, Weissenborn K, et al. (2022). Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial. Stroke, 53:2718-2729.","DOI":"10.1161\/STROKEAHA.121.037006"},{"key":"key-10.14336\/AD.2024.1688-67","doi-asserted-by":"crossref","unstructured":"Grothusen C, Umbreen S, Konrad I, Stellos K, Schulz C, Schmidt B, et al. (2007). EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. Arterioscler Thromb Vasc Biol, 27:1184-1190.","DOI":"10.1161\/ATVBAHA.106.138693"},{"key":"key-10.14336\/AD.2024.1688-68","doi-asserted-by":"crossref","unstructured":"Li TT, Fan ML, Hou SX, Li XY, Barry DM, Jin H, et al. (2015). A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischemic stroke and reperfusion injury. Br J Pharmacol, 172:3904-3916.","DOI":"10.1111\/bph.13178"},{"key":"key-10.14336\/AD.2024.1688-69","doi-asserted-by":"crossref","unstructured":"Hu H, Zhang XX, Wang YY, Chen SZ (2005). Honokiol inhibits arterial thrombosis through endothelial cell protection and stimulation of prostacyclin. Acta Pharmacol Sin, 26:1063-1068.","DOI":"10.1111\/j.1745-7254.2005.00164.x"},{"key":"key-10.14336\/AD.2024.1688-70","doi-asserted-by":"crossref","unstructured":"Florian P, Wonerow P, Harder S, Kuczka K, Dubar M, Graff J (2017). Anti-GPVI Fab SAR264565 effectively blocks GPVI function in ex vivo human platelets under arterial shear in a perfusion chamber. Eur J Clin Pharmacol, 73:949-956.","DOI":"10.1007\/s00228-017-2264-9"},{"key":"key-10.14336\/AD.2024.1688-71","doi-asserted-by":"crossref","unstructured":"Degen H, Borst O, Ziegler M, Mojica Munoz AK, Jamasbi J, Walker B, et al. (2017). ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions. J Am Heart Assoc, 6.","DOI":"10.1161\/JAHA.117.005991"},{"key":"key-10.14336\/AD.2024.1688-72","doi-asserted-by":"crossref","unstructured":"Nestele JA, Rohlfing AK, Dicenta V, Bild A, Ei\u00dfler D, Emschermann F, et al. (2021). Characterization of GPVI- or GPVI-CD39-Coated Nanoparticles and Their Impact on In Vitro Thrombus Formation. Int J Mol Sci, 23.","DOI":"10.3390\/ijms23010011"},{"key":"key-10.14336\/AD.2024.1688-73","doi-asserted-by":"crossref","unstructured":"Chang CH, Chung CH, Tu YS, Tsai CC, Hsu CC, Peng HC, et al. (2017). Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet. Arterioscler Thromb Vasc Biol, 37:1307-1314.","DOI":"10.1161\/ATVBAHA.116.308604"},{"key":"key-10.14336\/AD.2024.1688-74","doi-asserted-by":"crossref","unstructured":"Fontayne A, Meiring M, Lamprecht S, Roodt J, Demarsin E, Barbeaux P, et al. (2008). The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost, 100:670-677.","DOI":"10.1160\/TH08-02-0073"},{"key":"key-10.14336\/AD.2024.1688-75","doi-asserted-by":"crossref","unstructured":"Sanrattana W, Smits S, Barendrecht AD, van Kleef ND, El Otmani H, Zivkovic M, et al. (2022). Targeted SERPIN (TaSER): A dual-action antithrombotic agent that targets platelets for SERPIN delivery. J Thromb Haemost, 20:353-365.","DOI":"10.1111\/jth.15554"},{"key":"key-10.14336\/AD.2024.1688-76","doi-asserted-by":"crossref","unstructured":"Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A, et al. (2002). Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol, 22:187-192.","DOI":"10.1161\/hq0102.101520"},{"key":"key-10.14336\/AD.2024.1688-77","doi-asserted-by":"crossref","unstructured":"De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C (2012). von Willebrand factor: an emerging target in stroke therapy. Stroke, 43:599-606.","DOI":"10.1161\/STROKEAHA.111.628867"},{"key":"key-10.14336\/AD.2024.1688-78","doi-asserted-by":"crossref","unstructured":"Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring M, Depraetere H, Kotze HF, et al. (2002). Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood, 99:3623-3628.","DOI":"10.1182\/blood.V99.10.3623"},{"key":"key-10.14336\/AD.2024.1688-79","doi-asserted-by":"crossref","unstructured":"Gresele P, Momi S (2012). Inhibitors of the interaction between von Willebrand factor and platelet GPIb\/IX\/V. Handb Exp Pharmacol:287-309.","DOI":"10.1007\/978-3-642-29423-5_12"},{"key":"key-10.14336\/AD.2024.1688-80","doi-asserted-by":"crossref","unstructured":"Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A (2011). The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke, 42:2149-2153.","DOI":"10.1161\/STROKEAHA.111.616649"},{"key":"key-10.14336\/AD.2024.1688-81","doi-asserted-by":"crossref","unstructured":"Siller-Matula JM, Merhi Y, Tanguay JF, Duerschmied D, Wagner DD, McGinness KE, et al. (2012). ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol, 32:902-909.","DOI":"10.1161\/ATVBAHA.111.237529"},{"key":"key-10.14336\/AD.2024.1688-82","doi-asserted-by":"crossref","unstructured":"Kovacevic KD, Greisenegger S, Langer A, Gelbenegger G, Buchtele N, Pabinger I, et al. (2021). The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. Sci Rep, 11:3092.","DOI":"10.1038\/s41598-021-82747-7"},{"key":"key-10.14336\/AD.2024.1688-83","doi-asserted-by":"crossref","unstructured":"Sakai K, Someya T, Harada K, Yagi H, Matsui T, Matsumoto M (2020). Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab. Haematologica, 105:2631-2638.","DOI":"10.3324\/haematol.2019.235549"},{"key":"key-10.14336\/AD.2024.1688-84","doi-asserted-by":"crossref","unstructured":"Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, et al. (2011). Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood, 118:757-765.","DOI":"10.1182\/blood-2010-11-317859"},{"key":"key-10.14336\/AD.2024.1688-85","doi-asserted-by":"crossref","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Kn\u00f6bl P, Kremer Hovinga JA, et al. (2019). Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med, 380:335-346.","DOI":"10.1056\/NEJMoa1806311"},{"key":"key-10.14336\/AD.2024.1688-86","doi-asserted-by":"crossref","unstructured":"Shao B, Hoover C, Shi H, Kondo Y, Lee RH, Chen J, et al. (2022). Deletion of platelet CLEC-2 decreases GPIb\u03b1-mediated integrin \u03b1IIb\u03b23 activation and decreases thrombosis in TTP. Blood, 139:2523-2533.","DOI":"10.1182\/blood.2021012896"},{"key":"key-10.14336\/AD.2024.1688-87","doi-asserted-by":"crossref","unstructured":"Chang YW, Hsieh PW, Chang YT, Lu MH, Huang TF, Chong KY, et al. (2015). Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget, 6:42733-42748.","DOI":"10.18632\/oncotarget.5811"},{"key":"key-10.14336\/AD.2024.1688-88","doi-asserted-by":"crossref","unstructured":"Mammadova-Bach E, Mauler M, Braun A, Duerschmied D (2018). Autocrine and paracrine regulatory functions of platelet serotonin. Platelets, 29:541-548.","DOI":"10.1080\/09537104.2018.1478072"},{"key":"key-10.14336\/AD.2024.1688-89","doi-asserted-by":"crossref","unstructured":"Uchiyama S, Ozaki Y, Satoh K, Kondo K, Nishimaru K (2007). Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cerebrovasc Dis, 24:264-270.","DOI":"10.1159\/000105135"},{"key":"key-10.14336\/AD.2024.1688-90","doi-asserted-by":"crossref","unstructured":"Adams JW, Ramirez J, Shi Y, Thomsen W, Frazer J, Morgan M, et al. (2009). APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. J Pharmacol Exp Ther, 331:96-103.","DOI":"10.1124\/jpet.109.153189"},{"key":"key-10.14336\/AD.2024.1688-91","doi-asserted-by":"crossref","unstructured":"Ramirez JEM, Alarabi AB, Khasawneh FT, Alshbool FZ (2022). A Novel Antibody Targeting the Second Extracellular Loop of the Serotonin 5-HT2A Receptor Inhibits Platelet Function. Int J Mol Sci, 23.","DOI":"10.3390\/ijms23158794"},{"key":"key-10.14336\/AD.2024.1688-92","doi-asserted-by":"crossref","unstructured":"Rohlfing AK, Kolb K, Sigle M, Ziegler M, Bild A, M\u00fcnzer P, et al. (2022). ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury. Nat Commun, 13:1823.","DOI":"10.1038\/s41467-022-29341-1"},{"key":"key-10.14336\/AD.2024.1688-93","doi-asserted-by":"crossref","unstructured":"Poulsen SA, Quinn RJ (1998). Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem, 6:619-641.","DOI":"10.1016\/S0968-0896(98)00038-8"},{"key":"key-10.14336\/AD.2024.1688-94","doi-asserted-by":"crossref","unstructured":"Wolska N, Rozalski M (2019). Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy. Int J Mol Sci, 20.","DOI":"10.3390\/ijms20215475"},{"key":"key-10.14336\/AD.2024.1688-95","doi-asserted-by":"crossref","unstructured":"Coller BS (1997). Platelet GPIIb\/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest, 99:1467-1471.","DOI":"10.1172\/JCI119307"},{"key":"key-10.14336\/AD.2024.1688-96","doi-asserted-by":"crossref","unstructured":"Coller BS (1995). Blockade of platelet GPIIb\/IIIa receptors as an antithrombotic strategy. Circulation, 92:2373-2380.","DOI":"10.1161\/01.CIR.92.9.2373"},{"key":"key-10.14336\/AD.2024.1688-97","doi-asserted-by":"crossref","unstructured":"Hohmann JD, Wang X, Krajewski S, Selan C, Haller CA, Straub A, et al. (2013). Delayed targeting of CD39 to activated platelet GPIIb\/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding? Blood, 121:3067-3075.","DOI":"10.1182\/blood-2012-08-449694"},{"key":"key-10.14336\/AD.2024.1688-98","doi-asserted-by":"crossref","unstructured":"Martin V, Guillermet-Guibert J, Chicanne G, Cabou C, Jandrot-Perrus M, Plantavid M, et al. (2010). Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood, 115:2008-2013.","DOI":"10.1182\/blood-2009-04-217224"},{"key":"key-10.14336\/AD.2024.1688-99","doi-asserted-by":"crossref","unstructured":"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, et al. (2005). PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med, 11:507-514.","DOI":"10.1038\/nm1232"},{"key":"key-10.14336\/AD.2024.1688-100","doi-asserted-by":"crossref","unstructured":"Nylander S, W\u00e5gberg F, Andersson M, Sk\u00e4rby T, Gustafsson D (2015). Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase \u03b2 inhibition and aspirin in man. J Thromb Haemost, 13:1494-1502.","DOI":"10.1111\/jth.13027"},{"key":"key-10.14336\/AD.2024.1688-101","doi-asserted-by":"crossref","unstructured":"Zheng Z, Pinson JA, Mountford SJ, Orive S, Schoenwaelder SM, Shackleford D, et al. (2016). Discovery and antiplatelet activity of a selective PI3K\u03b2 inhibitor (MIPS-9922). Eur J Med Chem, 122:339-351.","DOI":"10.1016\/j.ejmech.2016.06.010"},{"key":"key-10.14336\/AD.2024.1688-102","doi-asserted-by":"crossref","unstructured":"Bussel J, Arnold DM, Grossbard E, Mayer J, Trelinski J, Homenda W, et al. (2018). Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol, 93:921-930.","DOI":"10.1002\/ajh.25125"},{"key":"key-10.14336\/AD.2024.1688-103","doi-asserted-by":"crossref","unstructured":"van Eeuwijk JM, Stegner D, Lamb DJ, Kraft P, Beck S, Thielmann I, et al. (2016). The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain Infarction. Arterioscler Thromb Vasc Biol, 36:1247-1253.","DOI":"10.1161\/ATVBAHA.115.306883"},{"key":"key-10.14336\/AD.2024.1688-104","doi-asserted-by":"crossref","unstructured":"Harbi MH, Smith CW, Alenazy FO, Nicolson PLR, Tiwari A, Watson SP, et al. (2022). Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs. Int J Mol Sci, 23.","DOI":"10.3390\/ijms23136982"},{"key":"key-10.14336\/AD.2024.1688-105","doi-asserted-by":"crossref","unstructured":"Tourdot BE, Holinstat M (2017). Targeting 12-Lipoxygenase as a Potential Novel Antiplatelet Therapy. Trends Pharmacol Sci, 38:1006-1015.","DOI":"10.1016\/j.tips.2017.08.001"},{"key":"key-10.14336\/AD.2024.1688-106","doi-asserted-by":"crossref","unstructured":"Yeung J, Apopa PL, Vesci J, Stolla M, Rai G, Simeonov A, et al. (2013). 12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity. Thromb Haemost, 110:569-581.","DOI":"10.1160\/TH13-01-0014"},{"key":"key-10.14336\/AD.2024.1688-107","doi-asserted-by":"crossref","unstructured":"Luci DK, Jameson JB, 2nd, Yasgar A, Diaz G, Joshi N, Kantz A, et al. (2014). Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase. J Med Chem, 57:495-506.","DOI":"10.1021\/jm4016476"},{"key":"key-10.14336\/AD.2024.1688-108","doi-asserted-by":"crossref","unstructured":"Tsai WC, Aleem AM, Tena J, Rivera-Velazquez M, Brah HS, Tripathi S, et al. (2021). Docking and mutagenesis studies lead to improved inhibitor development of ML355 for human platelet 12-lipoxygenase. Bioorg Med Chem, 46:116347.","DOI":"10.1016\/j.bmc.2021.116347"},{"key":"key-10.14336\/AD.2024.1688-109","doi-asserted-by":"crossref","unstructured":"Adili R, Tourdot BE, Mast K, Yeung J, Freedman JC, Green A, et al. (2017). First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis. Arterioscler Thromb Vasc Biol, 37:1828-1839.","DOI":"10.1161\/ATVBAHA.117.309868"},{"key":"key-10.14336\/AD.2024.1688-110","doi-asserted-by":"crossref","unstructured":"Busygina K, Jamasbi J, Seiler T, Deckmyn H, Weber C, Brandl R, et al. (2018). Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. Blood, 131:2605-2616.","DOI":"10.1182\/blood-2017-09-808808"},{"key":"key-10.14336\/AD.2024.1688-111","doi-asserted-by":"crossref","unstructured":"Denzinger V, Busygina K, Jamasbi J, Pekrul I, Spannagl M, Weber C, et al. (2019). Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO\/GS-4059, BGB-3111 and Evobrutinib. Thromb Haemost, 119:397-406.","DOI":"10.1055\/s-0039-1677744"},{"key":"key-10.14336\/AD.2024.1688-112","doi-asserted-by":"crossref","unstructured":"Karel MFA, Tullemans BME, D'Italia G, Lemmens TP, Claushuis TAM, Kuijpers MJE, et al. (2022). The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. Thromb Res, 212:72-80.","DOI":"10.1016\/j.thromres.2022.02.020"},{"key":"key-10.14336\/AD.2024.1688-113","doi-asserted-by":"crossref","unstructured":"Kohs TCL, Olson SR, Pang J, Jordan KR, Zheng TJ, Xie A, et al. (2022). Ibrutinib Inhibits BMX-Dependent Endothelial VCAM-1 Expression In Vitro and Pro-Atherosclerotic Endothelial Activation and Platelet Adhesion In Vivo. Cell Mol Bioeng, 15:231-243.","DOI":"10.1007\/s12195-022-00723-1"},{"key":"key-10.14336\/AD.2024.1688-114","doi-asserted-by":"crossref","unstructured":"Duan R, Goldmann L, Brandl R, Spannagl M, Weber C, Siess W, et al. (2021). Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time. Front Cardiovasc Med, 8:749022.","DOI":"10.3389\/fcvm.2021.749022"},{"key":"key-10.14336\/AD.2024.1688-115","doi-asserted-by":"crossref","unstructured":"Kim K, Hahm E, Li J, Holbrook LM, Sasikumar P, Stanley RG, et al. (2013). Platelet protein disulfide isomerase is required for thrombus formation but not for hemostasis in mice. Blood, 122:1052-1061.","DOI":"10.1182\/blood-2013-03-492504"},{"key":"key-10.14336\/AD.2024.1688-116","doi-asserted-by":"crossref","unstructured":"Wu Y, Ahmad SS, Zhou J, Wang L, Cully MP, Essex DW (2012). The disulfide isomerase ERp57 mediates platelet aggregation, hemostasis, and thrombosis. Blood, 119:1737-1746.","DOI":"10.1182\/blood-2011-06-360685"},{"key":"key-10.14336\/AD.2024.1688-117","doi-asserted-by":"crossref","unstructured":"Irfan M, Jeong D, Kwon HW, Shin JH, Park SJ, Kwak D, et al. (2018). Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling. Vascul Pharmacol, 109:45-55.","DOI":"10.1016\/j.vph.2018.06.002"},{"key":"key-10.14336\/AD.2024.1688-118","doi-asserted-by":"crossref","unstructured":"Guyette J, Cherubin P, Serrano A, Taylor M, Abedin F, O'Donnell M, et al. (2019). Quercetin-3-Rutinoside Blocks the Disassembly of Cholera Toxin by Protein Disulfide Isomerase. Toxins(Basel), 11.","DOI":"10.3390\/toxins11080458"},{"key":"key-10.14336\/AD.2024.1688-119","doi-asserted-by":"crossref","unstructured":"Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI (2017). Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight, 2:e89373.","DOI":"10.1172\/jci.insight.89373"},{"key":"key-10.14336\/AD.2024.1688-120","doi-asserted-by":"crossref","unstructured":"Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, et al. (2019). Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight, 4.","DOI":"10.1172\/jci.insight.125851"},{"key":"key-10.14336\/AD.2024.1688-121","doi-asserted-by":"crossref","unstructured":"Gaspar RS, da Silva SA, Stapleton J, Fontelles JLL, Sousa HR, Chagas VT, et al. (2019). Myricetin, the Main Flavonoid in Syzygium cumini Leaf, Is a Novel Inhibitor of Platelet Thiol Isomerases PDI and ERp5. Front Pharmacol, 10:1678.","DOI":"10.3389\/fphar.2019.01678"},{"key":"key-10.14336\/AD.2024.1688-122","doi-asserted-by":"crossref","unstructured":"Dangelmaier C, Manne BK, Liverani E, Jin J, Bray P, Kunapuli SP (2014). PDK1 selectively phosphorylates Thr(308) on Akt and contributes to human platelet functional responses. Thromb Haemost, 111:508-517.","DOI":"10.1160\/TH13-06-0484"},{"key":"key-10.14336\/AD.2024.1688-123","doi-asserted-by":"crossref","unstructured":"Tauber PA, Kratzer B, Schatzlmaier P, Smole U, K\u00f6hler C, Rausch L, et al. (2023). The small molecule inhibitor BX-795 uncouples IL-2 production from inhibition of Th2 inflammation and induces CD4(+) T cells resembling iTreg. Front Immunol, 14:1094694.","DOI":"10.3389\/fimmu.2023.1094694"},{"key":"key-10.14336\/AD.2024.1688-124","doi-asserted-by":"crossref","unstructured":"Piazza F, Manni S, Ruzzene M, Pinna LA, Gurrieri C, Semenzato G (2012). Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia, 26:1174-1179.","DOI":"10.1038\/leu.2011.385"},{"key":"key-10.14336\/AD.2024.1688-125","doi-asserted-by":"crossref","unstructured":"Nakanishi K, Toyoda H, Tanaka S, Yamamoto H, Komada Y, Gabazza EC, et al. (2010). Phosphoinositide 3-kinase induced activation and cytoskeletal translocation of protein kinase CK2 in protease activated receptor 1-stimulated platelets. Thromb Res, 126:511-516.","DOI":"10.1016\/j.thromres.2010.09.016"},{"key":"key-10.14336\/AD.2024.1688-126","doi-asserted-by":"crossref","unstructured":"M\u00fcnzer P, Walker-Allgaier B, Geue S, Langhauser F, Geuss E, Stegner D, et al. (2017). CK2\u03b2 regulates thrombopoiesis and Ca(2+)-triggered platelet activation in arterial thrombosis. Blood, 130:2774-2785.","DOI":"10.1182\/blood-2017-05-784413"},{"key":"key-10.14336\/AD.2024.1688-127","doi-asserted-by":"crossref","unstructured":"Ampofo E, M\u00fcller I, Dahmke IN, Eichler H, Montenarh M, Menger MD, et al. (2015). Role of protein kinase CK2 in the dynamic interaction of platelets, leukocytes and endothelial cells during thrombus formation. Thromb Res, 136:996-1006.","DOI":"10.1016\/j.thromres.2015.08.023"},{"key":"key-10.14336\/AD.2024.1688-128","doi-asserted-by":"crossref","unstructured":"Ryu SY, Kim S (2013). Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol, 720:391-400.","DOI":"10.1016\/j.ejphar.2013.09.064"},{"key":"key-10.14336\/AD.2024.1688-129","doi-asserted-by":"crossref","unstructured":"Borst O, Schmidt EM, M\u00fcnzer P, Sch\u00f6nberger T, Towhid ST, Elvers M, et al. (2012). The serum- and glucocorticoid-inducible kinase 1 (SGK1) influences platelet calcium signaling and function by regulation of Orai1 expression in megakaryocytes. Blood, 119:251-261.","DOI":"10.1182\/blood-2011-06-359976"},{"key":"key-10.14336\/AD.2024.1688-130","doi-asserted-by":"crossref","unstructured":"Chi OZ, Chiricolo A, Liu X, Patel N, Jacinto E, Weiss HR (2021). Inhibition of serum and glucocorticoid regulated kinases by GSK650394 reduced infarct size in early cerebral ischemia-reperfusion with decreased BBB disruption. Neurosci Lett, 762:136143.","DOI":"10.1016\/j.neulet.2021.136143"},{"key":"key-10.14336\/AD.2024.1688-131","doi-asserted-by":"crossref","unstructured":"Tsubaki M, Takeda T, Matsuda T, Seki S, Tomonari Y, Koizumi S, et al. (2021). Activation of Serum\/Glucocorticoid Regulated Kinase 1\/Nuclear Factor-\u03baB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010033"},{"key":"key-10.14336\/AD.2024.1688-132","doi-asserted-by":"crossref","unstructured":"Manke MC, Geue S, Coman C, Peng B, Kollotzek F, M\u00fcnzer P, et al. (2021). ANXA7 Regulates Platelet Lipid Metabolism and Ca(2+) Release in Arterial Thrombosis. Circ Res, 129:494-507.","DOI":"10.1161\/CIRCRESAHA.121.319207"},{"key":"key-10.14336\/AD.2024.1688-133","doi-asserted-by":"crossref","unstructured":"Kulkarni PP, Tiwari A, Singh N, Gautam D, Sonkar VK, Agarwal V, et al. (2019). Aerobic glycolysis fuels platelet activation: small-molecule modulators of platelet metabolism as anti-thrombotic agents. Haematologica, 104:806-818.","DOI":"10.3324\/haematol.2018.205724"},{"key":"key-10.14336\/AD.2024.1688-134","doi-asserted-by":"crossref","unstructured":"Flora GD, Nayak MK, Ghatge M, Kumskova M, Patel RB, Chauhan AK (2023). Mitochondrial pyruvate dehydrogenase kinases contribute to platelet function and thrombosis in mice by regulating aerobic glycolysis. Blood Adv, 7:2347-2359.","DOI":"10.1182\/bloodadvances.2023010100"},{"key":"key-10.14336\/AD.2024.1688-135","doi-asserted-by":"crossref","unstructured":"Zheng J (2012). Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett, 4:1151-1157.","DOI":"10.3892\/ol.2012.928"},{"key":"key-10.14336\/AD.2024.1688-136","doi-asserted-by":"crossref","unstructured":"Pfeiffer T, Schuster S, Bonhoeffer S (2001). Cooperation and competition in the evolution of ATP-producing pathways. Science, 292:504-507.","DOI":"10.1126\/science.1058079"},{"key":"key-10.14336\/AD.2024.1688-137","doi-asserted-by":"crossref","unstructured":"Nayak MK, Ghatge M, Flora GD, Dhanesha N, Jain M, Markan KR, et al. (2021). The metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis. Blood, 137:1658-1668.","DOI":"10.1182\/blood.2020007140"},{"key":"key-10.14336\/AD.2024.1688-138","doi-asserted-by":"crossref","unstructured":"Nayak MK, Dhanesha N, Doddapattar P, Rodriguez O, Sonkar VK, Dayal S, et al. (2018). Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis. Blood Adv, 2:2029-2038.","DOI":"10.1182\/bloodadvances.2018022392"},{"key":"key-10.14336\/AD.2024.1688-139","unstructured":"Jiang JK, Walsh MJ, Brimacombe KR, Anastasiou D, Yu Y, Israelsen WJ, et al.2010. ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model. In Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US)."},{"key":"key-10.14336\/AD.2024.1688-140","doi-asserted-by":"crossref","unstructured":"Wubben TJ, Pawar M, Weh E, Smith A, Sajjakulnukit P, Zhang L, et al. (2020). Small molecule activation of metabolic enzyme pyruvate kinase muscle isozyme 2, PKM2, circumvents photoreceptor apoptosis. Sci Rep, 10:2990.","DOI":"10.1038\/s41598-020-59999-w"},{"key":"key-10.14336\/AD.2024.1688-141","doi-asserted-by":"crossref","unstructured":"Lepropre S, Kautbally S, Octave M, Ginion A, Onselaer MB, Steinberg GR, et al. (2018). AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation. Blood, 132:1180-1192.","DOI":"10.1182\/blood-2018-02-831503"},{"key":"key-10.14336\/AD.2024.1688-142","doi-asserted-by":"crossref","unstructured":"Ma Y, Wang W, Devarakonda T, Zhou H, Wang XY, Salloum FN, et al. (2020). Functional analysis of molecular and pharmacological modulators of mitochondrial fatty acid oxidation. Sci Rep, 10:1450.","DOI":"10.1038\/s41598-020-58334-7"},{"key":"key-10.14336\/AD.2024.1688-143","doi-asserted-by":"crossref","unstructured":"Ravi S, Chacko B, Sawada H, Kramer PA, Johnson MS, Benavides GA, et al. (2015). Metabolic plasticity in resting and thrombin activated platelets. PLoS One, 10:e0123597.","DOI":"10.1371\/journal.pone.0123597"},{"key":"key-10.14336\/AD.2024.1688-144","doi-asserted-by":"crossref","unstructured":"Lin H, Patel S, Affleck VS, Wilson I, Turnbull DM, Joshi AR, et al. (2017). Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro Oncol, 19:43-54.","DOI":"10.1093\/neuonc\/now128"},{"key":"key-10.14336\/AD.2024.1688-145","doi-asserted-by":"crossref","unstructured":"Yoo HC, Yu YC, Sung Y, Han JM (2020). Glutamine reliance in cell metabolism. Exp Mol Med, 52:1496-1516.","DOI":"10.1038\/s12276-020-00504-8"},{"key":"key-10.14336\/AD.2024.1688-146","doi-asserted-by":"crossref","unstructured":"Guzzardo GM, Regling K (2022). Developmental Hemostasis: The Evolution of our Coagulation System. Neoreviews, 23:e82-e95.","DOI":"10.1542\/neo.23-2-e82"},{"key":"key-10.14336\/AD.2024.1688-147","doi-asserted-by":"crossref","unstructured":"Camire RM (2018). New Advances Along the Common Coagulation Pathway. Blood, 132:SCI-44.","DOI":"10.1182\/blood-2018-99-109557"},{"key":"key-10.14336\/AD.2024.1688-148","doi-asserted-by":"crossref","unstructured":"G\u00f6bel K, Eichler S, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG (2018). The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review. Front Immunol, 9:1731.","DOI":"10.3389\/fimmu.2018.01731"},{"key":"key-10.14336\/AD.2024.1688-149","doi-asserted-by":"crossref","unstructured":"Tweddell JS, Kharnaf M, Zafar F, Riggs KW, Reagor JA, Monia BP, et al. (2023). Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation. Blood Adv, 7:1404-1417.","DOI":"10.1182\/bloodadvances.2022007586"},{"key":"key-10.14336\/AD.2024.1688-150","doi-asserted-by":"crossref","unstructured":"May F, Krupka J, Fries M, Thielmann I, Pragst I, Weimer T, et al. (2016). FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis. Br J Haematol, 173:769-778.","DOI":"10.1111\/bjh.13990"},{"key":"key-10.14336\/AD.2024.1688-151","doi-asserted-by":"crossref","unstructured":"Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J, et al. (2009). Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med, 206:2381-2395.","DOI":"10.1084\/jem.20091007"},{"key":"key-10.14336\/AD.2024.1688-152","unstructured":"Sabine K, Sven J, Kerstin J, Moritz E, J\u00e9r\u00e9my L, Tanja S, et al. (2015). Abstract 18216: Essential Role of Platelet Glycoprotein Ib\u03b1 Dependent Thrombin-FXI Feedback Loop in Arterial Hypertension, Vascular Dysfunction and Inflammation. Circulation."},{"key":"key-10.14336\/AD.2024.1688-153","unstructured":"Tia CLK, Iv\u00e1n P-I, Helen HV, Monica TH, Joseph JS, Joseph EA, et al. (2022). Antiplatelet Effects of Inhibiting Coagulation Factor XI in a Diet-Induced Obesity Model of Early Atherosclerosis. Blood."},{"key":"key-10.14336\/AD.2024.1688-154","doi-asserted-by":"crossref","unstructured":"Puy C, Tucker EI, Ivanov IS, Gailani D, Smith SA, Morrissey JH, et al. (2016). Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI. PLoS One, 11:e0165172.","DOI":"10.1371\/journal.pone.0165172"},{"key":"key-10.14336\/AD.2024.1688-155","doi-asserted-by":"crossref","unstructured":"Emsley J, McEwan PA, Gailani D (2010). Structure and function of factor XI. Blood, 115:2569-2577.","DOI":"10.1182\/blood-2009-09-199182"},{"key":"key-10.14336\/AD.2024.1688-156","doi-asserted-by":"crossref","unstructured":"Gailani D, Geng Y, Verhamme I, Sun MF, Bajaj SP, Messer A, et al. (2014). The mechanism underlying activation of factor IX by factor XIa. Thromb Res, 133 Suppl 1:S48-51.","DOI":"10.1016\/j.thromres.2014.03.020"},{"key":"key-10.14336\/AD.2024.1688-157","doi-asserted-by":"crossref","unstructured":"Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, et al. (2021). The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood, 138:2173-2184.","DOI":"10.1182\/blood.2021011725"},{"key":"key-10.14336\/AD.2024.1688-158","doi-asserted-by":"crossref","unstructured":"Koch AW, Schiering N, Melkko S, Ewert S, Salter J, Zhang Y, et al. (2019). MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood, 133:1507-1516.","DOI":"10.1182\/blood-2018-10-880849"},{"key":"key-10.14336\/AD.2024.1688-159","doi-asserted-by":"crossref","unstructured":"Ahmad A, Karnik AA, Doshi R (2024). A Year in Review: Atrial Fibrillation 2023. J Innov Card Rhythm Manag, 15:5704-5708.","DOI":"10.19102\/icrm.2024.15017"},{"key":"key-10.14336\/AD.2024.1688-160","doi-asserted-by":"crossref","unstructured":"Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, et al. (2020). Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. Jama, 323:130-139.","DOI":"10.1001\/jama.2019.20687"},{"key":"key-10.14336\/AD.2024.1688-161","doi-asserted-by":"crossref","unstructured":"Poenou G, Dumitru Dumitru T, Lafaie L, Mismetti V, Heestermans M, Bertoletti L (2022). Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives. Vasc Health Risk Manag, 18:359-373.","DOI":"10.2147\/VHRM.S331614"},{"key":"key-10.14336\/AD.2024.1688-162","doi-asserted-by":"crossref","unstructured":"Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. (2021). Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med, 385:2161-2172.","DOI":"10.1056\/NEJMoa2113194"},{"key":"key-10.14336\/AD.2024.1688-163","doi-asserted-by":"crossref","unstructured":"Beale D, Dennison J, Boyce M, Mazzo F, Honda N, Smith P, et al. (2021). ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study. Br J Clin Pharmacol, 87:3177-3189.","DOI":"10.1111\/bcp.14732"},{"key":"key-10.14336\/AD.2024.1688-164","doi-asserted-by":"crossref","unstructured":"Wichaiyo S, Parichatikanond W, Visansirikul S, Saengklub N, Rattanavipanon W (2023). Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis. ACS Pharmacol Transl Sci, 6:970-981.","DOI":"10.1021\/acsptsci.3c00052"},{"key":"key-10.14336\/AD.2024.1688-165","doi-asserted-by":"crossref","unstructured":"Pollack CV, Jr., Kurz MA, Hayward NJ (2020). EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report. Crit Care Explor, 2:e0196.","DOI":"10.1097\/CCE.0000000000000196"},{"key":"key-10.14336\/AD.2024.1688-166","doi-asserted-by":"crossref","unstructured":"Callans DJ, Reynolds M, Zimetbaum PJ (2020). Electrophysiology's Identity Crisis: What our Clinical Trials Do and Do Not Say About Us. Arrhythm Electrophysiol Rev, 9:15-19.","DOI":"10.15420\/aer.2019.21"},{"key":"key-10.14336\/AD.2024.1688-167","doi-asserted-by":"crossref","unstructured":"Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, et al. (2022). Factor XIa inhibition with asundexian after acute non-cardioembolic ischemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet, 400:997-1007.","DOI":"10.1016\/S0140-6736(22)01588-4"},{"key":"key-10.14336\/AD.2024.1688-168","doi-asserted-by":"crossref","unstructured":"Chen W, Carvalho LP, Chan MY, Kini RM, Kang TS (2015). Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity. J Thromb Haemost, 13:248-261.","DOI":"10.1111\/jth.12797"},{"key":"key-10.14336\/AD.2024.1688-169","doi-asserted-by":"crossref","unstructured":"Chng WS, Li AWL, Lim JJM, Leong EJE, Amran FS, Kini RM, et al. (2022). A Factor XIa Inhibitor Engineered from Banded Krait Venom Toxin: Efficacy and Safety in Rodent Models of Arterial and Venous Thrombosis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071679"},{"key":"key-10.14336\/AD.2024.1688-170","unstructured":"Bethune C, Walsh M, Jung B, Yu R, Geary RS, Bhanot S (2017). Pharmacokinetics and Pharmacodynamics of Ionis-FXIRx, an Antisense Inhibitor of Factor XI, in Patients with End-Stage Renal Disease on Hemodialysis. Blood, 130:1116."},{"key":"key-10.14336\/AD.2024.1688-171","doi-asserted-by":"crossref","unstructured":"Al-Horani RA, Ponnusamy P, Mehta AY, Gailani D, Desai UR (2013). Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem, 56:867-878.","DOI":"10.1021\/jm301338q"},{"key":"key-10.14336\/AD.2024.1688-172","doi-asserted-by":"crossref","unstructured":"Al-Horani RA, Abdelfadiel EI, Afosah DK, Morla S, Sistla JC, Mohammed B, et al. (2019). A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding. J Thromb Haemost, 17:2110-2122.","DOI":"10.1111\/jth.14606"},{"key":"key-10.14336\/AD.2024.1688-173","doi-asserted-by":"crossref","unstructured":"Al-Horani RA, Gailani D, Desai UR (2015). Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. Thromb Res, 136:379-387.","DOI":"10.1016\/j.thromres.2015.04.017"},{"key":"key-10.14336\/AD.2024.1688-174","doi-asserted-by":"crossref","unstructured":"Ferri\u00e8re S, Kawecki C, Ottavi JF, Denis CV, Kauskot A, Christophe OD, et al. (2019). A single-domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor. J Thromb Haemost, 17:2035-2046.","DOI":"10.1111\/jth.14615"},{"key":"key-10.14336\/AD.2024.1688-175","doi-asserted-by":"crossref","unstructured":"Zhou Y, Qi X, Liu Y, Zhang F, Yan H (2019). DNA-Nanoscaffold-Assisted Selection of Femtomolar Bivalent Human \u03b1-Thrombin Aptamers with Potent Anticoagulant Activity. Chembiochem, 20:2494-2503.","DOI":"10.1002\/cbic.201900265"},{"key":"key-10.14336\/AD.2024.1688-176","doi-asserted-by":"crossref","unstructured":"Kolyadko VN, Layzer JM, Perry K, Sullenger BA, Krishnaswamy S (2024). An RNA aptamer exploits exosite-dependent allostery to achieve specific inhibition of coagulation factor IXa. Proc Natl Acad Sci U S A, 121:e2401136121.","DOI":"10.1073\/pnas.2401136121"},{"key":"key-10.14336\/AD.2024.1688-177","doi-asserted-by":"crossref","unstructured":"Lipinska-Gediga M (2017). Neutrophils, NETs, NETosis - old or new factors in sepsis and septic shock? Anaesthesiol Intensive Ther, 49:235-240.","DOI":"10.5603\/AIT.2017.0041"},{"key":"key-10.14336\/AD.2024.1688-178","doi-asserted-by":"crossref","unstructured":"Ruf W (2019). Links Between Complement Activation and Thrombosis. Blood, 134:SCI-40-SCI-40.","DOI":"10.1182\/blood-2019-121113"},{"key":"key-10.14336\/AD.2024.1688-179","doi-asserted-by":"crossref","unstructured":"Van Avondt K, Hartl D (2018). Mechanisms and disease relevance of neutrophil extracellular trap formation. Eur J Clin Invest, 48 Suppl 2:e12919.","DOI":"10.1111\/eci.12919"},{"key":"key-10.14336\/AD.2024.1688-180","doi-asserted-by":"crossref","unstructured":"Laridan E, Denorme F, Desender L, Fran\u00e7ois O, Andersson T, Deckmyn H, et al. (2017). Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol, 82:223-232.","DOI":"10.1002\/ana.24993"},{"key":"key-10.14336\/AD.2024.1688-181","doi-asserted-by":"crossref","unstructured":"Savchenko AS, Borissoff JI, Martinod K, De Meyer SF, Gallant M, Erpenbeck L, et al. (2014). VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia\/reperfusion injury in mice. Blood, 123:141-148.","DOI":"10.1182\/blood-2013-07-514992"},{"key":"key-10.14336\/AD.2024.1688-182","doi-asserted-by":"crossref","unstructured":"Ansari J, Vital SA, Yadav S, Gavins FNE (2023). Regulating Neutrophil PAD4\/NOX-Dependent Cerebrovasular Thromboinflammation. Int J Biol Sci, 19:852-864.","DOI":"10.7150\/ijbs.77434"},{"key":"key-10.14336\/AD.2024.1688-183","doi-asserted-by":"crossref","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. (2019). Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med, 381:2497-2505.","DOI":"10.1056\/NEJMoa1912388"},{"key":"key-10.14336\/AD.2024.1688-184","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz LE, Boeltz S, Bilyy R, Schauer C, Mahajan A, Widulin N, et al. (2019). Neutrophil Extracellular Traps Initiate Gallstone Formation. Immunity, 51:443-450.e444.","DOI":"10.1016\/j.immuni.2019.07.002"},{"key":"key-10.14336\/AD.2024.1688-185","doi-asserted-by":"crossref","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440:237-241.","DOI":"10.1038\/nature04516"},{"key":"key-10.14336\/AD.2024.1688-186","doi-asserted-by":"crossref","unstructured":"Opstal TSJ, Hoogeveen RM, Fiolet ATL, Silvis MJM, The SHK, Bax WA, et al. (2020). Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy. Circulation, 142:1996-1998.","DOI":"10.1161\/CIRCULATIONAHA.120.050560"},{"key":"key-10.14336\/AD.2024.1688-187","doi-asserted-by":"crossref","unstructured":"Rabbani A, Rafique A, Wang X, Campbell D, Wang D, Brownell N, et al. (2022). Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With Coronavirus Disease-19. Front Cardiovasc Med, 9:876718.","DOI":"10.3389\/fcvm.2022.876718"},{"key":"key-10.14336\/AD.2024.1688-188","doi-asserted-by":"crossref","unstructured":"Plessier A, Esposito-Far\u00e8se M, Baiges A, Shukla A, Garcia Pagan JC, De Raucourt E, et al. (2022). Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. Am J Hematol, 97:431-439.","DOI":"10.1002\/ajh.26474"},{"key":"key-10.14336\/AD.2024.1688-189","doi-asserted-by":"crossref","unstructured":"Chung C (2021). New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab. Ann Pharmacother, 55:330-343.","DOI":"10.1177\/1060028020941852"},{"key":"key-10.14336\/AD.2024.1688-190","doi-asserted-by":"crossref","unstructured":"Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, et al. (2020). Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest, 130:6151-6157.","DOI":"10.1172\/JCI141374"},{"key":"key-10.14336\/AD.2024.1688-191","doi-asserted-by":"crossref","unstructured":"Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, et al. (2015). Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest, 45:423-440.","DOI":"10.1111\/eci.12419"},{"key":"key-10.14336\/AD.2024.1688-192","doi-asserted-by":"crossref","unstructured":"Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, et al. (2020). The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol, 215:108450.","DOI":"10.1016\/j.clim.2020.108450"},{"key":"key-10.14336\/AD.2024.1688-193","doi-asserted-by":"crossref","unstructured":"Skendros P, Germanidis G, Mastellos DC, Antoniadou C, Gavriilidis E, Kalopitas G, et al. (2022). Complement C3 inhibition in severe COVID-19 using compstatin AMY-101. Sci Adv, 8:eabo2341.","DOI":"10.1126\/sciadv.abo2341"},{"key":"key-10.14336\/AD.2024.1688-194","doi-asserted-by":"crossref","unstructured":"Li WQ, Qin ZS, Chen S, Cheng D, Yang SC, Choi YMM, et al. (2022). Hirudin alleviates acute ischemic stroke by inhibiting NLRP3 inflammasome-mediated neuroinflammation: In vivo and in vitro approaches. Int Immunopharmacol, 110:108967.","DOI":"10.1016\/j.intimp.2022.108967"},{"key":"key-10.14336\/AD.2024.1688-195","doi-asserted-by":"crossref","unstructured":"Fei J, Wang H, Han J, Zhang X, Ma H, Qin X, et al. (2023). TXNIP activates NLRP3\/IL-1\u03b2 and participate in inflammatory response and oxidative stress to promote deep venous thrombosis. Exp Biol Med (Maywood), 248:1588-1597.","DOI":"10.1177\/15353702231191124"},{"key":"key-10.14336\/AD.2024.1688-196","doi-asserted-by":"crossref","unstructured":"Kennedy CR, Goya Grocin A, Kova\u010di\u010d T, Singh R, Ward JA, Shenoy AR, et al. (2021). A Probe for NLRP3 Inflammasome Inhibitor MCC950 Identifies Carbonic Anhydrase 2 as a Novel Target. ACS Chem Biol, 16:982-990.","DOI":"10.1021\/acschembio.1c00218"},{"key":"key-10.14336\/AD.2024.1688-197","doi-asserted-by":"crossref","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 377:1119-1131.","DOI":"10.1056\/NEJMoa1707914"},{"key":"key-10.14336\/AD.2024.1688-198","doi-asserted-by":"crossref","unstructured":"Blann AD, Nadar SK, Lip GY (2003). The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J, 24:2166-2179.","DOI":"10.1016\/j.ehj.2003.08.021"},{"key":"key-10.14336\/AD.2024.1688-199","doi-asserted-by":"crossref","unstructured":"Sabrkhany S, Griffioen AW, Pineda S, Sanders L, Mattheij N, van Geffen JP, et al. (2016). Sunitinib uptake inhibits platelet function in cancer patients. Eur J Cancer, 66:47-54.","DOI":"10.1016\/j.ejca.2016.07.016"},{"key":"key-10.14336\/AD.2024.1688-200","doi-asserted-by":"crossref","unstructured":"Feng Q, Wang M, Muhtar E, Wang Y, Zhu H (2021). Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models. Int J Nanomedicine, 16:5777-5795.","DOI":"10.2147\/IJN.S316863"},{"key":"key-10.14336\/AD.2024.1688-201","doi-asserted-by":"crossref","unstructured":"Agrati C, Bordoni V, Sacchi A, Petrosillo N, Nicastri E, Del Nonno F, et al. (2021). Elevated P-Selectin in Severe Covid-19: Considerations for Therapeutic Options. Mediterr J Hematol Infect Dis, 13:e2021016.","DOI":"10.4084\/mjhid.2021.016"},{"key":"key-10.14336\/AD.2024.1688-202","doi-asserted-by":"crossref","unstructured":"Enlimomab Acute Stroke Trial Investigators (2001). Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology, 57:1428-1434.","DOI":"10.1212\/WNL.57.8.1428"},{"key":"key-10.14336\/AD.2024.1688-203","doi-asserted-by":"crossref","unstructured":"Kovacs RJ, Maldonado G, Azaro A, Fern\u00e1ndez MS, Romero FL, Sepulveda-S\u00e1nchez JM, et al. (2015). Cardiac Safety of TGF-\u03b2 Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol, 15:309-323.","DOI":"10.1007\/s12012-014-9297-4"},{"key":"key-10.14336\/AD.2024.1688-204","doi-asserted-by":"crossref","unstructured":"Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Gr\u00e9goire JC, et al. (2013). Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol, 61:2048-2055.","DOI":"10.1016\/j.jacc.2013.03.003"},{"key":"key-10.14336\/AD.2024.1688-205","doi-asserted-by":"crossref","unstructured":"Kluft C, Sidelmann JJ, Gram JB (2017). Assessing Safety of Thrombolytic Therapy. Semin Thromb Hemost, 43:300-310.","DOI":"10.1055\/s-0036-1584130"},{"key":"key-10.14336\/AD.2024.1688-206","doi-asserted-by":"crossref","unstructured":"Su M, Dai Q, Chen C, Zeng Y, Chu C, Liu G (2020). Nano-Medicine for Thrombosis: A Precise Diagnosis and Treatment Strategy. Nanomicro Lett, 12:96.","DOI":"10.1007\/s40820-020-00434-0"},{"key":"key-10.14336\/AD.2024.1688-207","doi-asserted-by":"crossref","unstructured":"Bulbake U, Doppalapudi S, Kommineni N, Khan W (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"key-10.14336\/AD.2024.1688-208","doi-asserted-by":"crossref","unstructured":"Zhang N, Li C, Zhou D, Ding C, Jin Y, Tian Q, et al. (2018). Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis. Acta Biomater, 70:227-236.","DOI":"10.1016\/j.actbio.2018.01.038"},{"key":"key-10.14336\/AD.2024.1688-209","doi-asserted-by":"crossref","unstructured":"Jamasbi J, Ayabe K, Goto S, Nieswandt B, Peter K, Siess W (2017). Platelet receptors as therapeutic targets: Past, present and future. Thromb Haemost, 117:1249-1257.","DOI":"10.1160\/TH16-12-0911"},{"key":"key-10.14336\/AD.2024.1688-210","doi-asserted-by":"crossref","unstructured":"Vaidya B, Agrawal GP, Vyas SP (2011). Platelets directed liposomes for the delivery of streptokinase: development and characterization. Eur J Pharm Sci, 44:589-594.","DOI":"10.1016\/j.ejps.2011.10.004"},{"key":"key-10.14336\/AD.2024.1688-211","doi-asserted-by":"crossref","unstructured":"Bardania H, Shojaosadati SA, Kobarfard F, Dorkoosh F, Zadeh ME, Naraki M, et al. (2017). Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity. J Thromb Thrombolysis, 43:184-193.","DOI":"10.1007\/s11239-016-1440-6"},{"key":"key-10.14336\/AD.2024.1688-212","doi-asserted-by":"crossref","unstructured":"Liang C, Huang T, Zhang X, Rao H, Jin Z, Pan X, et al. (2022). cRGD Urokinase Liposomes for Thrombolysis in Rat Model of Acute Pulmonary Microthromboembolism. Drug Des Devel Ther, 16:801-816.","DOI":"10.2147\/DDDT.S351021"},{"key":"key-10.14336\/AD.2024.1688-213","doi-asserted-by":"crossref","unstructured":"Li J, Zhang X, Mo Y, Huang T, Rao H, Tan Z, et al. (2022). Urokinase-loaded cyclic RGD-decorated liposome targeted therapy for in-situ thrombus of pulmonary arteriole of pulmonary hypertension. Front Bioeng Biotechnol, 10:1038829.","DOI":"10.3389\/fbioe.2022.1038829"},{"key":"key-10.14336\/AD.2024.1688-214","doi-asserted-by":"crossref","unstructured":"Shaw GJ, Meunier JM, Huang SL, Lindsell CJ, McPherson DD, Holland CK (2009). Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. Thromb Res, 124:306-310.","DOI":"10.1016\/j.thromres.2009.01.008"},{"key":"key-10.14336\/AD.2024.1688-215","doi-asserted-by":"crossref","unstructured":"Ruan R, Chen S, Su J, Liu N, Feng H, Xiao P, et al. (2024). Targeting Nanomotor with Near-Infrared\/Ultrasound Triggered-Transformation for Polystage-Propelled Cascade Thrombolysis and Multimodal Imaging Diagnosis. Adv Healthc Mater, 13:e2302591.","DOI":"10.1002\/adhm.202302591"},{"key":"key-10.14336\/AD.2024.1688-216","doi-asserted-by":"crossref","unstructured":"Fan Y, Liu L, Li F, Zhou H, Ye Y, Yuan C, et al. (2022). Construction of ultrasound-responsive urokinase precise controlled-release nanoliposome applied for thrombolysis. Front Bioeng Biotechnol, 10:923365.","DOI":"10.3389\/fbioe.2022.923365"},{"key":"key-10.14336\/AD.2024.1688-217","doi-asserted-by":"crossref","unstructured":"Mukhametova LI, Aisina RB, Zakharyan EM, Karakhanov EA, Gershkovich KB, Varfolomeyev SD (2017). Thrombolytic and fibrinogenolytic properties of bioconjugate streptokinase-polyamidoamine dendrimers in vitro. Thromb Res, 154:50-52.","DOI":"10.1016\/j.thromres.2017.04.008"},{"key":"key-10.14336\/AD.2024.1688-218","doi-asserted-by":"crossref","unstructured":"Liao J, Ren X, Yang B, Li H, Zhang Y, Yin Z (2019). Targeted thrombolysis by using c-RGD-modified N,N,N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase. Drug Dev Ind Pharm, 45:88-95.","DOI":"10.1080\/03639045.2018.1522324"},{"key":"key-10.14336\/AD.2024.1688-219","doi-asserted-by":"crossref","unstructured":"Huang Y, Wang J, Guo Y, Park SY, Yang H, Lu A, et al. (2024). Selective binding of cationic fibrinogen-mimicking chitosan nanoparticles to activated platelets and efficient drug release for antithrombotic therapy. Int J Biol Macromol, 268:131742.","DOI":"10.1016\/j.ijbiomac.2024.131742"},{"key":"key-10.14336\/AD.2024.1688-220","doi-asserted-by":"crossref","unstructured":"Fang N, Liu J, Hou J, Zhong Y, Luo Y, Hu L, et al. (2022). Magnet-Guided Bionic System with LIFU Responsiveness and Natural Thrombus Tropism for Enhanced Thrombus-Targeting Ability. Int J Nanomedicine, 17:2019-2039.","DOI":"10.2147\/IJN.S357050"},{"key":"key-10.14336\/AD.2024.1688-221","doi-asserted-by":"crossref","unstructured":"Hasanpour A, Esmaeili F, Hosseini H, Amani A (2021). Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies. Mater Sci Eng C Mater Biol Appl, 118:111427.","DOI":"10.1016\/j.msec.2020.111427"},{"key":"key-10.14336\/AD.2024.1688-222","doi-asserted-by":"crossref","unstructured":"Zhang W, Wang J, Xie Z, Zou H, Chen Q, Xu L, et al. (2022). Antithrombotic Therapy by Regulating the ROS-Mediated Thrombosis Microenvironment and Specific Nonpharmaceutical Thrombolysis Using Prussian Blue Nanodroplets. Small, 18:e2106252.","DOI":"10.1002\/smll.202106252"},{"key":"key-10.14336\/AD.2024.1688-223","doi-asserted-by":"crossref","unstructured":"Xu L, Zhou Y, Li N, Yang A, Qi H (2024). Platelet membrane encapsulated curcumin nanomaterial-mediated specific thrombolysis and anti-thrombotic treatment among pregnant women. Biomater Sci, 12:3163-3174.","DOI":"10.1039\/D4BM00149D"},{"key":"key-10.14336\/AD.2024.1688-224","doi-asserted-by":"crossref","unstructured":"Bi F, Zhang J, Su Y, Tang YC, Liu JN (2009). Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. Biomaterials, 30:5125-5130.","DOI":"10.1016\/j.biomaterials.2009.06.006"},{"key":"key-10.14336\/AD.2024.1688-225","doi-asserted-by":"crossref","unstructured":"Polyak B, Medved M, Lazareva N, Steele L, Patel T, Rai A, et al. (2016). Magnetic Nanoparticle-Mediated Targeting of Cell Therapy Reduces In-Stent Stenosis in Injured Arteries. ACS Nano, 10:9559-9569.","DOI":"10.1021\/acsnano.6b04912"},{"key":"key-10.14336\/AD.2024.1688-226","doi-asserted-by":"crossref","unstructured":"Banik B, Surnar B, Askins BW, Banerjee M, Dhar S (2020). Dual-Targeted Synthetic Nanoparticles for Cardiovascular Diseases. ACS Appl Mater Interfaces, 12:6852-6862.","DOI":"10.1021\/acsami.9b19036"},{"key":"key-10.14336\/AD.2024.1688-227","doi-asserted-by":"crossref","unstructured":"Zhang Y, Cheng S, He Y, Tang C, Liu F, Sun Y, et al. (2021). Activated Platelet-Homing Nanoplatform for Targeting Magnetic Resonance Imaging of Aneurysm-Related Thrombus in Rabbits. ACS Appl Mater Interfaces, 13:50705-50715.","DOI":"10.1021\/acsami.1c13539"},{"key":"key-10.14336\/AD.2024.1688-228","doi-asserted-by":"crossref","unstructured":"Tang X, Manamanchaiyaporn L, Zhou Q, Huang C, Li L, Li Z, et al. (2022). Synergistic Integration and Pharmacomechanical Function of Enzyme-Magnetite Nanoparticle Swarms for Low-Dose Fast Thrombolysis. Small, 18:e2202848.","DOI":"10.1002\/smll.202202848"},{"key":"key-10.14336\/AD.2024.1688-229","doi-asserted-by":"crossref","unstructured":"Li Z, Zhang S, Wang Q, Xu Y, Li Y, Chen X, et al. (2024). Untethered & Stiffness-Tunable Ferromagnetic Liquid Robots for Cleaning Thrombus in Complex Blood Vessels. Adv Mater:e2409142.","DOI":"10.1002\/adma.202409142"},{"key":"key-10.14336\/AD.2024.1688-230","doi-asserted-by":"crossref","unstructured":"Xu J, Zhou Y, Nie H, Xiong Z, OuYang H, Huang L, et al. (2020). Hyperthermia-triggered UK release nanovectors for deep venous thrombosis therapy. J Mater Chem B, 8:787-793.","DOI":"10.1039\/C9TB01851D"},{"key":"key-10.14336\/AD.2024.1688-231","doi-asserted-by":"crossref","unstructured":"Chang LH, Chuang EY, Cheng TM, Lin C, Shih CM, Wu AT, et al. (2021). Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent. Acta Biomater, 134:686-701.","DOI":"10.1016\/j.actbio.2021.07.072"},{"key":"key-10.14336\/AD.2024.1688-232","doi-asserted-by":"crossref","unstructured":"Di L, Thomas A, Switala L, Kalikasingh K, Lapping S, Nayak L, et al. (2023). Surface Geometry of Cargo-less Gold Nanoparticles Is a Driving Force for Selective Targeting of Activated Neutrophils to Reduce Thrombosis in Antiphospholipid Syndrome. Nano Lett, 23:9690-9696.","DOI":"10.1021\/acs.nanolett.3c02075"},{"key":"key-10.14336\/AD.2024.1688-233","doi-asserted-by":"crossref","unstructured":"Xie C, Zhang L (2023). Design and characterization of antithrombotic ClEKnsTy-Au nanoparticles as diagnostic and therapeutic reagents. Phys Chem Chem Phys, 25:20422-20429.","DOI":"10.1039\/D3CP01000G"},{"key":"key-10.14336\/AD.2024.1688-234","doi-asserted-by":"crossref","unstructured":"Freedman JE (2008). Oxidative stress and platelets. Arterioscler Thromb Vasc Biol, 28:s11-16.","DOI":"10.1161\/ATVBAHA.107.159178"},{"key":"key-10.14336\/AD.2024.1688-235","doi-asserted-by":"crossref","unstructured":"Jun H, Jeon C, Kim S, Song N, Jo H, Yang M, et al. (2023). Nanoassemblies of Self-Immolative Boronate-Bridged Retinoic Acid Dimeric Prodrug as a Clot-Targeted Self-Deliverable Antithrombotic Nanomedicine. ACS Nano, 17:12336-12346.","DOI":"10.1021\/acsnano.3c01503"},{"key":"key-10.14336\/AD.2024.1688-236","doi-asserted-by":"crossref","unstructured":"Wang Y, Jian C, Long Y, Xu X, Song Y, Yin Z (2023). H(2)O(2)-triggered \"off\/on signal\" nanoparticles target P-selectin for the non-invasive and contrast-enhanced theranostics for arterial thrombosis. Acta Biomater, 158:769-781.","DOI":"10.1016\/j.actbio.2022.12.026"},{"key":"key-10.14336\/AD.2024.1688-237","doi-asserted-by":"crossref","unstructured":"Leopold JA, Loscalzo J (2009). Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med, 47:1673-1706.","DOI":"10.1016\/j.freeradbiomed.2009.09.009"},{"key":"key-10.14336\/AD.2024.1688-238","doi-asserted-by":"crossref","unstructured":"Xia Y, Chen R, Ke Y, Han Q, Ma Z, Shi Q (2023). ROS-responsive phenylboronic ester-based nanovesicles as multifunctional drug delivery systems for the treatment of inflammatory and thrombotic complications. Biomater Sci, 11:7805-7816.","DOI":"10.1039\/D3BM01427D"},{"key":"key-10.14336\/AD.2024.1688-239","doi-asserted-by":"crossref","unstructured":"Zhang Y, Chen Y, Lo C, Zhuang J, Angsantikul P, Zhang Q, et al. (2019). Inhibition of Pathogen Adhesion by Bacterial Outer Membrane-Coated Nanoparticles. Angew Chem Int Ed Engl, 58:11404-11408.","DOI":"10.1002\/anie.201906280"},{"key":"key-10.14336\/AD.2024.1688-240","doi-asserted-by":"crossref","unstructured":"Zhang F, Mundaca-Uribe R, Gong H, Esteban-Fern\u00e1ndez de \u00c1vila B, Beltr\u00e1n-Gast\u00e9lum M, Karshalev E, et al. (2019). A Macrophage-Magnesium Hybrid Biomotor: Fabrication and Characterization. Adv Mater, 31:e1901828.","DOI":"10.1002\/adma.201901828"},{"key":"key-10.14336\/AD.2024.1688-241","doi-asserted-by":"crossref","unstructured":"Pawlowski CL, Li W, Sun M, Ravichandran K, Hickman D, Kos C, et al. (2017). Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis. Biomaterials, 128:94-108.","DOI":"10.1016\/j.biomaterials.2017.03.012"},{"key":"key-10.14336\/AD.2024.1688-242","doi-asserted-by":"crossref","unstructured":"Wang B, Chen G, Urabe G, Xie R, Wang Y, Shi X, et al. (2018). A paradigm of endothelium-protective and stent-free anti-restenotic therapy using biomimetic nanoclusters. Biomaterials, 178:293-301.","DOI":"10.1016\/j.biomaterials.2018.06.025"},{"key":"key-10.14336\/AD.2024.1688-243","doi-asserted-by":"crossref","unstructured":"Quan X, Han Y, Lu P, Ding Y, Wang Q, Li Y, et al. (2022). Annexin V-Modified Platelet-Biomimetic Nanomedicine for Targeted Therapy of Acute Ischemic Stroke. Adv Healthc Mater, 11:e2200416.","DOI":"10.1002\/adhm.202200416"},{"key":"key-10.14336\/AD.2024.1688-244","doi-asserted-by":"crossref","unstructured":"Guo X, Hong T, Zang J, Shao R, Hou X, Wang K, et al. (2022). Thrombus-specific\/responsive biomimetic nanomedicine for spatiotemporal thrombolysis and alleviation of myocardial ischemia\/reperfusion injury. J Nanobiotechnology, 20:531.","DOI":"10.1186\/s12951-022-01686-1"},{"key":"key-10.14336\/AD.2024.1688-245","doi-asserted-by":"crossref","unstructured":"Li S, Zhang K, Ma Z, Zhang W, Song Z, Wang W, et al. (2022). Biomimetic Nanoplatelets to Target Delivery Hirudin for Site-Specific Photothermal\/Photodynamic Thrombolysis and Preventing Venous Thrombus Formation. Small, 18:e2203184.","DOI":"10.1002\/smll.202203184"},{"key":"key-10.14336\/AD.2024.1688-246","doi-asserted-by":"crossref","unstructured":"Xiao H, Meng X, Songtao L, Li Z, Fang S, Wang Y, et al. (2024). Combined drug anti-deep vein thrombosis therapy based on platelet membrane biomimetic targeting nanotechnology. Biomaterials, 311:122670.","DOI":"10.1016\/j.biomaterials.2024.122670"},{"key":"key-10.14336\/AD.2024.1688-247","doi-asserted-by":"crossref","unstructured":"Zhao Y, Xie R, Yodsanit N, Ye M, Wang Y, Gong S (2020). Biomimetic fibrin-targeted and H(2)O(2)-responsive nanocarriers for thrombus therapy. Nano Today, 35.","DOI":"10.1016\/j.nantod.2020.100986"},{"key":"key-10.14336\/AD.2024.1688-248","doi-asserted-by":"crossref","unstructured":"Zhu L, Lian W, Yu N, Meng J, Zeng H, Wang Y, et al. (2024). Erythrocyte-Membrane-Camouflaged Magnetic Nanocapsules With Photothermal\/Magnetothermal Effects for Thrombolysis. Adv Healthc Mater, 13:e2400127.","DOI":"10.1002\/adhm.202400127"},{"key":"key-10.14336\/AD.2024.1688-249","doi-asserted-by":"crossref","unstructured":"Wang X, Gkanatsas Y, Palasubramaniam J, Hohmann JD, Chen YC, Lim B, et al. (2016). Thrombus-Targeted Theranostic Microbubbles: A New Technology towards Concurrent Rapid Ultrasound Diagnosis and Bleeding-free Fibrinolytic Treatment of Thrombosis. Theranostics, 6:726-738.","DOI":"10.7150\/thno.14514"},{"key":"key-10.14336\/AD.2024.1688-250","doi-asserted-by":"crossref","unstructured":"Tu L, Liao Z, Luo Z, Wu Y-L, Herrmann A, Huo S (2021). Ultrasound-controlled drug release and drug activation for cancer therapy. 1:20210023.","DOI":"10.1002\/EXP.20210023"},{"key":"key-10.14336\/AD.2024.1688-251","doi-asserted-by":"crossref","unstructured":"Hu L, Xu J, Zhang W, Wang J, Fang N, Luo Y, et al. (2022). A Synergistic and Efficient Thrombolytic Nanoplatform: A Mechanical Method of Blasting Combined with Thrombolytic Drugs. Int J Nanomedicine, 17:5229-5246.","DOI":"10.2147\/IJN.S382964"},{"key":"key-10.14336\/AD.2024.1688-252","doi-asserted-by":"crossref","unstructured":"Wang S, Guo X, Xiu W, Liu Y, Ren L, Xiao H, et al. (2020). Accelerating thrombolysis using a precision and clot-penetrating drug delivery strategy by nanoparticle-shelled microbubbles. Sci Adv, 6:eaaz8204.","DOI":"10.1126\/sciadv.aaz8204"},{"key":"key-10.14336\/AD.2024.1688-253","doi-asserted-by":"crossref","unstructured":"Wang L, Wang J, Hao J, Dong Z, Wu J, Shen G, et al. (2021). Guiding Drug Through Interrupted Bloodstream for Potentiated Thrombolysis by C-Shaped Magnetic Actuation System In Vivo. Adv Mater, 33:e2105351.","DOI":"10.1002\/adma.202105351"},{"key":"key-10.14336\/AD.2024.1688-254","doi-asserted-by":"crossref","unstructured":"Gao B, Xu J, Zhou J, Zhang H, Yang R, Wang H, et al. (2021). Multifunctional pathology-mapping theranostic nanoplatforms for US\/MR imaging and ultrasound therapy of atherosclerosis. Nanoscale, 13:8623-8638.","DOI":"10.1039\/D1NR01096D"},{"key":"key-10.14336\/AD.2024.1688-255","doi-asserted-by":"crossref","unstructured":"Zhang D, Zhang C, Lan S, Huang Y, Liu J, Li J, et al. (2019). Near-Infrared Light Activated Thermosensitive Ion Channel to Remotely Control Transgene System for Thrombolysis Therapy. Small, 15:e1901176.","DOI":"10.1002\/smll.201901176"},{"key":"key-10.14336\/AD.2024.1688-256","doi-asserted-by":"crossref","unstructured":"Burnouf T, Chen CH, Tan SJ, Tseng CL, Lu KY, Chang LH, et al. (2019). A bioinspired hyperthermic macrophage-based polypyrrole-polyethylenimine (Ppy-PEI) nanocomplex carrier to prevent and disrupt thrombotic fibrin clots. Acta Biomater, 96:468-479.","DOI":"10.1016\/j.actbio.2019.06.053"},{"key":"key-10.14336\/AD.2024.1688-257","doi-asserted-by":"crossref","unstructured":"Lu TY, Chiang CY, Fan YJ, Jheng PR, Qui\u00f1ones ED, Liu KT, et al. (2021). Dual-Targeting Glycol Chitosan\/Heparin-Decorated Polypyrrole Nanoparticle for Augmented Photothermal Thrombolytic Therapy. ACS Appl Mater Interfaces, 13:10287-10300.","DOI":"10.1021\/acsami.0c20940"},{"key":"key-10.14336\/AD.2024.1688-258","doi-asserted-by":"crossref","unstructured":"Song J, Kang X, Wang L, Ding D, Kong D, Li W, et al. (2023). Near-infrared-II photoacoustic imaging and photo-triggered synergistic treatment of thrombosis via fibrin-specific homopolymer nanoparticles. Nat Commun, 14:6881.","DOI":"10.1038\/s41467-023-42691-8"},{"key":"key-10.14336\/AD.2024.1688-259","doi-asserted-by":"crossref","unstructured":"Wang Z, Jiang N, Jiang Z, Wang H, Guo Y, Zhong F, et al. (2024). Dual-mode nanoprobe strategy integrating ultrasound and near-infrared light for targeted and synergistic arterial thrombolysis. J Nanobiotechnology, 22:311.","DOI":"10.1186\/s12951-024-02562-w"},{"key":"key-10.14336\/AD.2024.1688-260","doi-asserted-by":"crossref","unstructured":"van den Broek WWA, Mani N, Azzahhafi J, Ten Berg JM (2023). CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials. Am J Cardiovasc Drugs, 23:165-172.","DOI":"10.1007\/s40256-022-00565-2"},{"key":"key-10.14336\/AD.2024.1688-261","doi-asserted-by":"crossref","unstructured":"Plomondon ME, Lambert-Kerzner AC, Jennewein X, Fagan K, McCreight M, Fehling KB, et al. (2015). Variability of antithrombotic dosing among veterans presenting with acute coronary syndrome. J Am Heart Assoc, 4.","DOI":"10.1161\/JAHA.114.001433"},{"key":"key-10.14336\/AD.2024.1688-262","doi-asserted-by":"crossref","unstructured":"Fan P, Gao Y, Zheng M, Xu T, Schoenhagen P, Jin Z (2018). Recent progress and market analysis of anticoagulant drugs. J Thorac Dis, 10:2011-2025.","DOI":"10.21037\/jtd.2018.03.95"},{"key":"key-10.14336\/AD.2024.1688-263","doi-asserted-by":"crossref","unstructured":"Boivin-Proulx L-A, Bainey KR, Marquis-Gravel G, Graham MM (2024). Potent P2Y12 Inhibitor Selection and De-escalation Strategies in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: Systematic Review and Meta-analysis. CJC Open, 6:677-688.","DOI":"10.1016\/j.cjco.2023.11.024"},{"key":"key-10.14336\/AD.2024.1688-264","doi-asserted-by":"crossref","unstructured":"Xu J, Zhang Y, Nie G (2021). Intelligent antithrombotic nanomedicines: Progress, opportunities, and challenges. 2:20200145.","DOI":"10.1002\/VIW.20200145"},{"key":"key-10.14336\/AD.2024.1688-265","doi-asserted-by":"crossref","unstructured":"Sim MMS, Shiferawe S, Wood JP (2023). Novel strategies in antithrombotic therapy: targeting thrombosis while preserving hemostasis. Front Cardiovasc Med, 10:1272971.","DOI":"10.3389\/fcvm.2023.1272971"},{"key":"key-10.14336\/AD.2024.1688-266","doi-asserted-by":"crossref","unstructured":"La CC, Smith SA, Vappala S, Adili R, Luke CE, Abbina S, et al. (2023). Smart thrombosis inhibitors without bleeding side effects via charge tunable ligand design. Nat Commun, 14:2177.","DOI":"10.1038\/s41467-023-37709-0"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:12:57Z","timestamp":1741997577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2024.1688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":266,"URL":"https:\/\/doi.org\/10.14336\/ad.2024.1688","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}